Clinical Trial Update: Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating telitacicept plus low-dose IL-2 for efficacy and immunological effects in systemic lupus erythematosus, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)
• Telitacicept

Snippet

Sponsor: Liu Tian | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: RECRUITING